Mobile, ALNCT05232916Now EnrollingIRB Ready

Breast Cancer Clinical Trial in Mobile, AL

Access cutting-edge breast cancer treatment through this phase 3 clinical trial at a research site in Mobile. Study-provided care at no cost to qualified participants.

Sponsored by Greenwich LifeSciences, Inc.

Quick Self-Assessment

See if you qualify for this Mobile location

Preparing your pre-screening questions…

Expert Care in Mobile

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This Mobile Location

Check if you qualify for this breast cancer clinical trial in Mobile, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Mobile

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Mobile site if eligible
  4. 4Begin participation

About This Breast Cancer Study in Mobile

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third o

Sponsor: Greenwich LifeSciences, Inc.

Who Can Participate

Inclusion Criteria

Histologically confirmed diagnosis of HER2/neu positive primary breast cancer for all tumors biopsied at diagnosis (multifocal, multicentric, or synchronous contralateral disease)
Completion of both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy
Stage I, II, or III at presentation with pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy -OR- Stage III at presentation with pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy
The subject can begin study therapy within one year of completion of adjuvant trastuzumab-based therapy and any other standard therapies, but, study therapy can be administered concurrently with endocrine therapy.
No clinical evidence of residual or persistent breast cancer per treating physician assessment
Adequate organ function
Negative pregnancy test or evidence of post-menopausal status
If of childbearing potential, willing to use a form of highly effective contraception
Subject must both reside in and have been treated for their cancer in the country in which the clinical site is located.

Exclusion Criteria

Stage IV cancer or metastatic breast cancer at any time
Inflammatory breast cancer
Receiving other investigational agents
Receiving chemotherapy
Requiring long-term systemic treatment with corticosteroids or other immunosuppressive therapy
History of immunodeficiency or active autoimmune disease
A history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factors such as sargramostim, yeast-derived products, or any component of the investigational product
Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin
Active infection
Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Mobile?

Yes, this clinical trial (NCT05232916) has an active research site in Mobile, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Mobile, AL

If you're searching for breast cancer treatment options in Mobile, AL, this clinical trial (NCT05232916) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Mobile research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Mobile, AL

See all breast cancer clinical trials recruiting in Mobile — not just this study.

Browse Breast Cancer Trials in Mobile →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Mobile?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Mobile, AL